Multimodality therapy of an acquired factor V inhibitor

35Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Acquired inhibitors of factor V are rare causes of clinical bleeding, whose severity ranges from mild to life-threatening. Optimal treatment of patients with factor V inhibitors is uncertain. We report on our successful treatment approach in a patient with spontaneous, life-threatening intracranial bleeding caused by a factor V inhibitor. The patient deteriorated after initial treatment with fresh-frozen plasma and platelet transfusions. He was subsequently treated with a combination of plasma exchange and chemotherapy, which led to complete recovery. Our experience suggests that plasma exchange may be life-saving in cases of severe bleeding caused by factor V inhibitors. The use of plasmapheresis in conjunction with chemotherapy is an efficacious and well-tolerated treatment and should be considered in patients with factor V inhibitors.

Cite

CITATION STYLE

APA

Fu, Y. X., Kaufman, R., Rudolph, A. E., Collum, S. E., & Blinder, M. A. (1996). Multimodality therapy of an acquired factor V inhibitor. American Journal of Hematology, 51(4), 315–318. https://doi.org/10.1002/(SICI)1096-8652(199604)51:4<315::AID-AJH11>3.0.CO;2-D

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free